Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.875
+0.003 (0.29%)
At close: Jan 28, 2025, 4:00 PM
0.860
-0.015 (-1.68%)
After-hours: Jan 28, 2025, 5:00 PM EST
Atossa Therapeutics Employees
Atossa Therapeutics had 12 employees as of December 31, 2023. The number of employees increased by 1 or 9.09% compared to the previous year.
Employees
12
Change (1Y)
1
Growth (1Y)
9.09%
Revenue / Employee
n/a
Profits / Employee
-$2,242,583
Market Cap
110.05M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ATOS News
- 5 days ago - Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density - GlobeNewsWire
- 7 weeks ago - Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 7 weeks ago - Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research - GlobeNewsWire
- 2 months ago - Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire